Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

CSL Ltd (ASX: CSL) shares are shaking off the broader market selling action today to push higher.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed yesterday trading for $245.21. In afternoon trade on Thursday, shares are changing hands for $246.51 apiece, up 0.5%.

For some context, the ASX 200 is down 0.5% at this same time.

Despite today's welcome lift, CSL shares remain down 12.3% in 2025.

So, is the Aussie biotech giant now trading for a bargain, or does the stock have further to fall?

For some greater insight into that multi-million-dollar question, we defer to Crispin Murray, head of Australian equities at Pendal.

Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

Can CSL shares return to outperform?

On 14 December 2021, CSL announced its intention to acquire Vifor Pharma, an iron deficiency and nephrology treatment company, for US$11.7 billion. That acquisition was completed on 9 August 2022.

But a lot of investors, including Murray, were critical of the cost of that acquisition. And many reacted by hitting their sell buttons.

Indeed, CSL stock remains down around 17% since 10 December 2021, just prior to the Vifor acquisition announcement.

"Their return on capital collapsed. And clearly they overpaid for an average business," Murray said (quoted by The Australian Financial Review).

However, Murray believes the future is looking brighter for CSL shares.

"Our bet is the sort of failures of the last five years have finally permeated into the psyche of the company. They realise they need to improve," he said.

According to Murray:

This remains an incredibly good business. Patients rely on their products and their long-term requirement for those products.

The fund manager forecasts that management will be more cost-conscious moving ahead. And he also said he expects CSL to engage in a share buyback within the "next few months".

"We think the market will flip in terms of looking at that as a return to its better growth days," he said.

As for the potential impact of United States President Donald Trump's threatened tariffs on pharmaceuticals, Murray added:

We think there's a downside of maybe 10% to 15%… but that's assuming the company doesn't respond. Companies can realign where they produce things. They can do that within two or three years.

What's the latest from the ASX 200 biotech stock?

The last price-sensitive news to directly impact CSL shares was the company's half-year results release on 11 February.

Highlights included a 5% year-on-year increase in revenue in constant currency to US$8.48 billion. And net profit after tax (NPAT) for the six months was up 7% in constant currency to US$2.04 billion.

This led management to boost the interim dividend by 15% to AU$2.07 per CSL share.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »